← Eichor
Condition: Locally Advanced Bladder Urothelial Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Locally Advanced Bladder Urothelial Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Phase 1 · 1 location(s) · Emory University · NCT04878029A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07492628A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Phase 2 · 221 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04879329A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · 286 location(s) · Eli Lilly and Company · NCT07218380FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Phase 1 · 82 location(s) · Eli Lilly and Company · NCT05614739EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
Phase 2 · 1 location(s) · Peking University Third Hospital · NCT07647289Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT05239624KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People
Phase 1/Phase 2 · 16 location(s) · Merck Sharp & Dohme LLC · NCT07232602Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT052676269MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06823427A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Phase 3 · 71 location(s) · Merck Sharp & Dohme LLC · NCT07419295Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Phase 1/Phase 2 · 115 location(s) · Pfizer · NCT07421700A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and
Phase 4 · 1 location(s) · Mayo Clinic · NCT06764095Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Partic
Phase 2/Phase 3 · 100 location(s) · Daiichi Sankyo · NCT07129993
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.